Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific.
Anumana expands AI cardiac care platform with support from Boston Scientific
Related Articles
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the…June 21, 2023
Uncertainty Estimation in Healthcare AI
Building on our previous discussion of imbalanced regression, we now turn to another critical challenge: uncertainty estimation. While addressing data imbalance helps models pay attention to rare cases, we must also…September 05, 2025
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine
Mayo Clinic News Network: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians…April 13, 2021